Spencer, A., Horvath, N., Gibson, J., Prince, H.M., Herrmann, R., Bashford, J., … Taylor, K. (2005). Prospective randomized trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation. Bone Marrow Transplantation, 35, 971–977.
Patients in the study group received 910 mg/m2 IV amifostine 15–30 minutes prior to 200 mg/m2 melphalan prior to autotransplant for multiple myeloma (MM).
This was a multicenter study conducted between May 1999 and November 2000.
This was an open label, randomized study.
The World Health Organization (WHO) scale for mucositis, median duration of mucositis, duration of total parenteral nutrition (TPN), and duration of narcotics use were recorded.
This study provided weak statistical evidence for the use of amifostine.